S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NASDAQ:CRNC

Cerence Stock Forecast, Price & News

$119.17
-5.54 (-4.44 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$116.22
Now: $119.17
$129.09
50-Day Range
$85.23
MA: $102.18
$121.35
52-Week Range
$11.39
Now: $119.17
$129.09
Volume674,071 shs
Average Volume717,992 shs
Market Capitalization$4.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.85
Cerence Inc. provides AI-powered assistants and innovations for connected and autonomous vehicles It offers edge software components; cloud-connected components; toolkits; applications; and virtual assistant coexistence and professional services. The company also provides conversational artificial intelligence, including voice recognition, natural language understanding, and artificial intelligence services. Cerence Inc. is headquartered in Burlington, Massachusetts.

MarketRank

Overall MarketRank

1.85 out of 5 stars

Computer And Technology Sector

119th out of 1,501 stocks

Prepackaged Software Industry

21st out of 284 stocks

Analyst Opinion: 2.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Prepackaged software
Sub-IndustryN/A
Current SymbolNASDAQ:CRNC
CUSIPN/A
CIKN/A
Phone857-362-7300
Employees1,500
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$329.65 million
Cash Flow$0.25 per share
Book Value$26.08 per share

Profitability

Net Income$-20,630,000.00

Miscellaneous

Market Cap$4.49 billion
Next Earnings DateN/A
OptionableNot Optionable
$119.17
-5.54 (-4.44 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRNC News and Ratings via Email

Sign-up to receive the latest news and ratings for CRNC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cerence (NASDAQ:CRNC) Frequently Asked Questions

How has Cerence's stock been impacted by Coronavirus?

Cerence's stock was trading at $18.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRNC shares have increased by 540.4% and is now trading at $119.17.
View which stocks have been most impacted by COVID-19
.

Is Cerence a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerence in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cerence stock.
View analyst ratings for Cerence
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cerence?

Wall Street analysts have given Cerence a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cerence wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Cerence's earnings last quarter?

Cerence Inc. (NASDAQ:CRNC) posted its earnings results on Sunday, November, 15th. The company reported $0.61 EPS for the quarter, beating the Zacks' consensus estimate of $0.34 by $0.27. The firm earned $90.88 million during the quarter, compared to the consensus estimate of $79.14 million. Cerence had a negative net margin of 6.26% and a negative trailing twelve-month return on equity of 0.92%.
View Cerence's earnings history
.

What guidance has Cerence issued on next quarter's earnings?

Cerence issued an update on its first quarter 2021 Pre-Market earnings guidance on Monday, November, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $85-90 million, compared to the consensus revenue estimate of $82.1 million.

What price target have analysts set for CRNC?

10 equities research analysts have issued 1-year price objectives for Cerence's stock. Their forecasts range from $24.00 to $120.00. On average, they expect Cerence's stock price to reach $76.70 in the next twelve months. This suggests that the stock has a possible downside of 35.6%.
View analysts' price targets for Cerence
or view Wall Street analyst' top-rated stocks.

Who are some of Cerence's key competitors?

What other stocks do shareholders of Cerence own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerence investors own include NVIDIA (NVDA), Square (SQ), Fastly (FSLY), DocuSign (DOCU), PayPal (PYPL), Shopify (SHOP), Teladoc Health (TDOC), Alteryx (AYX), Lumentum (LITE) and salesforce.com (CRM).

Who are Cerence's key executives?

Cerence's management team includes the following people:
  • Mr. Sanjay Dhawan, CEO & Director (Age 57, Pay $1.48M)
  • Mr. Mark J. Gallenberger, Chief Financial Officer (Age 57, Pay $838.32k)
  • Dr. Stefan Ortmanns, Exec. VP of Core Automotive (Age 57, Pay $1.43M)
  • Mr. Prateek Kathpal, Chief Technology Officer
  • Ms. Bridget Collins, Chief Information Officer
  • Mr. Richard Yerganian, VP of Investor Relations
  • Ms. Leanne Fitzgerald, Gen. Counsel & Sec. (Age 56)
  • Mr. Egon Jungheim, Sr. VP Global Sales
  • Mr. Richard Mack, Chief Marketing Officer
  • Mr. Sachin Sahney, Chief HR Officer

What is Cerence's stock symbol?

Cerence trades on the NASDAQ under the ticker symbol "CRNC."

Who are Cerence's major shareholders?

Cerence's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Paradigm Capital Management Inc. NY (0.77%), Handelsinvest Investeringsforvaltning (0.29%), Sara Bay Financial (0.13%), Raymond James Trust N.A. (0.04%), Acorn Financial Advisory Services Inc. ADV (0.04%) and Janney Montgomery Scott LLC (0.03%). Company insiders that own Cerence stock include Kristi Ann Matus, Leanne Fitzgerald, Mark J Gallenberger, Sanjay Dhawan, Stefan Ortmanns and Thomas L Beaudoin.
View institutional ownership trends for Cerence
.

Which institutional investors are selling Cerence stock?

CRNC stock was sold by a variety of institutional investors in the last quarter, including Handelsinvest Investeringsforvaltning, Hohimer Wealth Management LLC, Hohimer Wealth Management LLC, Paradigm Capital Management Inc. NY, We Are One Seven LLC, Acorn Financial Advisory Services Inc. ADV, Strs Ohio, and Janney Montgomery Scott LLC. Company insiders that have sold Cerence company stock in the last year include Kristi Ann Matus, Leanne Fitzgerald, Mark J Gallenberger, Sanjay Dhawan, Stefan Ortmanns, and Thomas L Beaudoin.
View insider buying and selling activity for Cerence
or view top insider-selling stocks.

Which institutional investors are buying Cerence stock?

CRNC stock was bought by a variety of institutional investors in the last quarter, including Sara Bay Financial, Vivid Financial Management Inc., Park Avenue Securities LLC, Optimum Investment Advisors, International Assets Investment Management LLC, Baldwin Brothers Inc. MA, Raymond James Trust N.A., and Nisa Investment Advisors LLC.
View insider buying and selling activity for Cerence
or or view top insider-buying stocks.

How do I buy shares of Cerence?

Shares of CRNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cerence's stock price today?

One share of CRNC stock can currently be purchased for approximately $119.17.

How big of a company is Cerence?

Cerence has a market capitalization of $4.49 billion and generates $329.65 million in revenue each year. The company earns $-20,630,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Cerence employs 1,500 workers across the globe.

What is Cerence's official website?

The official website for Cerence is www.cerence.com.

How can I contact Cerence?

Cerence's mailing address is 15 WAYSIDE ROAD, BURLINGTON MA, 01803. The company can be reached via phone at 857-362-7300 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.